ACE and COVID-19: Therefore, shifting the balance toward a lower and hence a more anti-inflammatory ACE1/ACE2 ratio is essential when considering therapies targeting ACE2, particularly since a peaking in the inflammatory response and subsequent cytokine storm have been reported in advanced diseased COVID-19 patients [17].